The study is based on new oral matrix tablets based on Kollidon®SR and chitosan, formulated in order to optimize the low oral bioavailability of amiodarone, a class III antiarrhythmic drug. Pharmacotechnical characterization included the analysis of flowability and compressibility properties (flow time, friction coefficient, angle of repose, Hausner ratio, Carr Index), and of pharmaco-chemical characteristics (mass and dose uniformity, thickness, diameter, mechanical strength, friability, degree of softening, in vitro release profile) of the tablets obtained using direct compression method. The results obtained have shown that both Kollidon®SR and chitosan may be used as matrix forming agents when combined with amiodarone. In vitro dissolution tests revealed that the nine formulations studied provided a prolonged release of amiodarone when compared to an industrial pharmaceutical product formulated as conventional release tablets.